ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 740 • 2013 ACR/ARHP Annual Meeting

    Clinically Apparent Arterial Thrombosis In Persons With Systemic Vasculitis

    Alexander Tsoukas1, Christian A. Pineau2, Sasha Bernatsky3, Lawrence Joseph4 and Patrick Belisle5, 1Rheumatology, McGill University, Montreal, QC, Canada, 2Rheumatology, McGill University Health Center, Montreal, QC, Canada, 3Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, 4McGill University, Montreal, QC, Canada, 5Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Systemic  vasculitides  are a group of heterogeneous, autoimmune disorders characterized by inflammation of blood vessels. As with other autoimmune disorders, inflammation and long-term medical…
  • Abstract Number: 741 • 2013 ACR/ARHP Annual Meeting

    Granulomatosis With Polyangiitis Central Nervous System Involvement: Presentation and Management

    Gonzalo De Luna1,2, Benjamin Terrier3, Pierre Kaminsky4, Francois Maurier5, Roser Solans6, Raphaèle Seror7, Xavier Puéchal8, Luc Mouthon9 and Loic Guillevin10, 1Medecine Interne, Cochin University Hospital, Paris, France, 2Internal Medicine, Hospital Ramon y Cajal, Madrid, Spain, 3Internal Medicine, Cochin University Hospital, Paris, France, 4Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, 5HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 6Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain, 7Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, 8National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 9Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 10Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France

    Background/Purpose: Granulomatosis with polyangiitis (GPA), a small-sized–vessel vasculitis, commonly involves ear, nose & throat (ENT), lungs and kidneys, and, more rarely, the central nervous system…
  • Abstract Number: 742 • 2013 ACR/ARHP Annual Meeting

    Safety Of Remission Induction With Rituximab Versus Cyclosphosphamide In Patients 65 and Older With Severe ANCA-Associated Vasculitis

    Eli Miloslavsky1, Ulrich Specks2, Peter A Merkel3, Philip Seo4, Robert F. Spiera5, Carol A. Langford6, Gary S. Hoffman7, Cees G.M. Kallenberg8, E. William St. Clair9, Nadia Tchao10, Linna Ding11, David Ikle12, Brett Jepson12, Paul Brunetta13 and John H. Stone14, 1Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, 2Mayo Clinic, Rochester, MN, 3Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 5Rheumatology, Hospital for Special Surgery, New York, NY, 6Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 7Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 8Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 9Medicine, Duke University Medical Center, Durham, NC, 10Immune Tolerance Network, Bethesda, MD, 11NIAID, Bethesda, MD, 12Rho, Chapel Hill, NC, 13Biotherapeutics, Genentech, So San Francisco, CA, 14Rheumatology, Massachusetts General Hospital, Boston, MA

    Background/Purpose: Retrospective studies have demonstrated that patients of advanced age with systemic vasculitis experience a higher mortality and adverse events than their younger counterparts. However,…
  • Abstract Number: 743 • 2013 ACR/ARHP Annual Meeting

    Efficacy Of Rituximab For Otolaryngologic (ENT) Manifestations Of Granulomatosis With Polyangiitis (GPA, Wegener’s granulomatosis)

    Lindsay Lally1, Robert Lebovics2, Wei-Ti Huang3 and Robert F. Spiera1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Otolaryngology, St. Luke's-Roosevelt Hospital Center, New York, NY, 3Biostatistics, Hospital for Special Surgery, New York, NY

    Background/Purpose: ENT involvement is the most prevalent manifestation of GPA.  Rituximab (RTX) is a proven effective remission induction therapy for severe GPA with vasculitic manifestations. …
  • Abstract Number: 744 • 2013 ACR/ARHP Annual Meeting

    Relationship Between Infectious Side Effects and Immunoglobulin Levels In The Maintenance Rituximab Vs Azathioprine For ANCA-Associated Vasculitides Trial

    Loic Guillevin1, Christian Pagnoux2, Alexandre Karras3, Chahera Khouatra4, Olivier Aumaître5, Pascal Cohen6, Olivier Decaux7, Hélène Desmurs-Clavel8, Pierre Gobert9, Thomas Quemeneur10, Claire Blanchard-Delaunay11, Pascal Godmer12, Xavier Puechal13, Pierre-Louis Carron14, Pierre-Yves Hatron15, Nicolas Limal16, Mohamed Hamidou17, Francois Maurier18, Thomas Papo19, Matthias Büchler20, Bernard Bonnotte21, Philippe Ravaud22 and Luc Mouthon23, 1Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 2Internal Medicine, Hôpital Cochin, PARIS, France, 3Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 4CHU Lyon, Lyon, France, 5Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 7Department of Internal Medicine, Rennes University Hospital, Rennes, France, 8University of Lyon, LYON, France, 9Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 10Internal medicine, CHR de Valenciennes, Valenciennes, France, 11Internal Medicine, Hôpital de Niort, Niort, France, 12Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, 13Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 14Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, 15Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, 16Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, 17Internal Medicine Department, Nantes University Hospital, Nantes, France, 18HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 19Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 20Nephrology, University Hospital of Tours, TOURS, France, 21Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, 22Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 23Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France

    Background/Purpose: MAINRITSAN trial (NCT 00748644) results demonstrated that 500 mg of rituximab (RTX) every 6 months was superior to azathioprine (AZA) to maintain ANCA-associated–vasculitis (AAV)…
  • Abstract Number: 745 • 2013 ACR/ARHP Annual Meeting

    Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials

    Carolina Mejia-Otero1, Carlos J. Lozada2 and Luis Arias-Urdaneta3, 1Internal Medicine, Mount Sinai Medical Center, Miami, FL, 2Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, 3Rheumatology, Mount Sinai Medical Center, Miami Beach, FL

    Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…
  • Abstract Number: 746 • 2013 ACR/ARHP Annual Meeting

    Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides

    Joanna Robson1, Helen Doll2, Ravi Suppiah3, Oliver Flossmann4, Lorraine Harper5, Peter Hoglund6, David Jayne7, Alfred Mahr8, Kerstin Westman9 and Raashid A. Luqmani10, 1Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 2Department of Population Health, University of East Anglia, Norwich, United Kingdom, 3Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 4Nephrology, Royal Berkshire Hospital, Reading, United Kingdom, 5Nephrology, University of Birmingham, Birmingham, United Kingdom, 6Competence Centre fo Clinical Research, Skane University Hospital, Lund, Sweden, 7Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 8Department of Internal Medicine, Hospital Saint-Louis, Paris, France, 9Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, 10Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom

    Background/Purpose: Granulomatosis with polyangiitis [Wegener's] (GPA) and microscopic polyangiitis (MPA) are antineutrophil-cytoplasm antibody associated vasculitides (AAVs). Damage is quantified by the Vasculitis Damage Index (VDI).…
  • Abstract Number: 747 • 2013 ACR/ARHP Annual Meeting

    Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis

    Eli Miloslavsky1, Ulrich Specks2, Peter A. Merkel3, Philip Seo4, Robert F. Spiera5, Carol A. Langford6, Gary S. Hoffman7, Cees G.M. Kallenberg8, E. William St. Clair9, Nadia Tchao10, Linna Ding11, David Ikle12, Brett Jepson12, Paul Brunetta13 and John H. Stone14, 1Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, 2Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 4Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 5Rheumatology, Hospital for Special Surgery, New York, NY, 6Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 7Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 8Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 9Medicine, Duke University Medical Center, Durham, NC, 10Immune Tolerance Network, Bethesda, MD, 11NIAID, Bethesda, MD, 12Rho, Chapel Hill, NC, 13Biotherapeutics, Genentech, So San Francisco, CA, 14Rheumatology, Massachusetts General Hospital, Boston, MA

    Background/Purpose: The great majority of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) achieve disease remission initially, but relapses occur in up to…
  • Abstract Number: 715 • 2013 ACR/ARHP Annual Meeting

    Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression In CD4+ T Cells

    Dipak R. Patel, Gabriela Gorelik and Bruce C. Richardson, Internal Medicine, University of Michigan, Ann Arbor, MI

    Background/Purpose: CD4+CD28- T cells are enriched in chronic inflammatory diseases like rheumatoid arthritis (RA) and lupus.  They are cytotoxic and resistant to apoptosis.  Compared to…
  • Abstract Number: 707 • 2013 ACR/ARHP Annual Meeting

    Different Location and Extent Of Impaired Perfusion Of The Choroid Plexus In Primary and Secondary Raynaud’s Phenomenon

    Francesca Ingegnoli1, Roberta Gualtierotti2, Luisa Pierro3, Elisabetta Miserocchi4, Giulio Modorati5, Claudia Del turco3, Marco Gagliardi3, Giuseppe Parrinello6, Tommaso Schioppo2 and Pier Luigi Meroni7, 1Dept. of clinical sciences and community health, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, 2Dept. of clinical sciences and community health, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, 3Department of Ophthalmology, Vita-Salute University, San Raffaele Scientific Institute, Milano, Italy, 4Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy, 5San Raffaele Scientific Institute, Ocular immunology and uveitis service, Milano, Italy, 6Department of Ophthalmology,, Vita-Salute University, San Raffaele Scientific Institute, Milano, Italy, 7Division of Rheumatology, Gaetano Pini Institute, Milano, Italy

    Background/Purpose: Raynaud’s phenomenon (RP) is a disorder characterized by systemic vascular dysregulation which has been related with vasospasms and retinal blood flow abnormalities. Nevertheless among…
  • Abstract Number: 708 • 2013 ACR/ARHP Annual Meeting

    Intravenous Immunoglobulin May Be An Effective Therapy In Scleroderma Patients With Refractory Active Diffuse Cutaneous Disease

    Corrie Poelman1, Laura K. Hummers2, Fredrick M. Wigley2, Cynthia Anderson1, Francesco Boin2 and Ami A. Shah2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: A subset of patients with active diffuse cutaneous scleroderma has refractory disease despite traditional immunosuppressive therapy. In this retrospective observational study, we investigated whether…
  • Abstract Number: 709 • 2013 ACR/ARHP Annual Meeting

    Nilotinib (Tasigna™) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial – One Year Results

    Jessica K. Gordon1, Cynthia Magro2, Uzunma Udeh1, Daniele Lerner1, Horatio F. Wildman3, Wei-Ti Huang4, Mary K. Crow5 and Robert F. Spiera1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Dermatopathology, Weill-Cornell Medical Center, New York, NY, 3Dermatology, Weill-Cornell Medical Center, New York, NY, 4Biostatistics, Hospital for Special Surgery, New York, NY, 5Department of Medicine, Hospital for Special Surgery, New York, NY

    Background/Purpose: Tyrosine kinase inhibitors (TKI) are under investigation for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc.)  Nilotinib is a second-generation TKI which selectively antagonizes c-abl and…
  • Abstract Number: 710 • 2013 ACR/ARHP Annual Meeting

    Interleukin-6 Driven STAT3 Phosphorylation In Circulating Lymphocytes Is Specific For CD4+ T Cells In Early Rheumatoid Arthritis

    Amy E. Anderson1, Christine Routledge1, Philip Mawson2, John D. Isaacs3 and Arthur G. Pratt3, 1Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, 2Musculoskeletal Directorate, The Freeman Hospital, Newcastle upon Tyne, United Kingdom, 3Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease, caused by a breakdown in self tolerance. Robust biomarkers are needed which, as well having…
  • Abstract Number: 711 • 2013 ACR/ARHP Annual Meeting

    1,25(OH)2D3 Inhibits Th17 Cytokine Production and RORγt Expression Through GATA3/IL4-Dependent and -Independent Mechanisms

    Wendy Dankers1, Jan Piet van Hamburg2,3, Anne-Marie Mus1, Patrick S. Asmawidjaja1, Johannes van Leeuwen4, Rudi W. Hendriks5, Louis Boon6, Edgar Colin7 and Erik Lubberts1,8, 1Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 2Rheumatology, Erasmus MC, Rotterdam, Netherlands, 3Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 4Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 5Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 6Bioceros, Utrecht, Netherlands, 7Department of Rheumatology, ZGT, Almelo, Netherlands, 8Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands

    Background/Purpose: Vitamin D has suppressive effects on autoimmune diseases, such as rheumatoid arthritis (RA). One important mechanism of disease suppression by vitamin D is inhibition…
  • Abstract Number: 712 • 2013 ACR/ARHP Annual Meeting

    Increased IL-23 Receptor Expression Is Observed On KIR3DL2+ CD4+ T Cells In Ankylosing Spondylitis and Correlates With IL-23R Polymorphisms

    A. Ridley1, C. Cohen2, T. Karaderi2, S. Kollnberger3, I. Wong-Baeza3, J. Shaw3, P. Wordsworth3 and P. Bowness3, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, 2Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

    Background/Purpose: T helper 17 (Th17) cells are a subset of pro-inflammatory CD4+ T cells implicated in a number of inflammatory arthritides including the Spondyloarthritides (SpAs). …
  • « Previous Page
  • 1
  • …
  • 2199
  • 2200
  • 2201
  • 2202
  • 2203
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology